Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Efficacy of Pergolide in Treatment of Restless Legs Syndrome
Neurol 62:1391-1397, Trenkwalder,C.,et al, 2004
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Tourette's Syndrome Improvement with Pergolide in a Randomized, Double-Blind, Crossover Trial
Neurol 54:1310-1315, Gilbert,D.L.,et al, 2000
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
Randomized,Double-Blind,Placebo-Controlled Trial of Pergolide in Restless Leg Syndrome
Neurol 51:1599-1602, Earley,C.J.,et al, 1998
Retroperitoneal Fibrosis in a Patient with Parkinson's Disease Treated with Pergolide
Clin NeuroPharmacol 18:277-279, Jimenez-Jimenez,F.J.,et al, 1995
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Agonist Substitution in Advanced Parkinson's Disease
Neurol 39:1121-1122, Goetz,C.G.,et al, 1989
Double-Blind Assessment of Potential Pergolide-Induced Cardiotoxicity
Neurol 36:993-995, Kurlan,R.,et al, 1986
Long-Term Study of Pergolide in Parkinson's Disease
Neurol 35:296-299, Jankovic,J., 1985
Pergolide in the Treatment of Parkinson's Disease
Neurol 34:983-986, Mear,J.,et al, 1984
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Controlled Trial of Pergolide Mesylate in Parkinson's Disease & Progressive Supranuclear Palsy
Neurol 33:505-507, Jankovic,J., 1983
Comparison of Pergolide & Bromocriptine Therapy in Parkinsonism
Neurol 33:1009-1014, LeWitt,P.A.,et al, 1983
Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth Hormone
NEJM 309:704-709, Kleinberg,D.K.,et al, 1983
Pergolide in Parkinson's Disease
Arch Neurol 40:785-787, Goetz,C.G.,et al, 1983
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
Pergolide Mesylate & Idiopathic Parkinson Disease
Neurol 32:1175-1179, Tanner,C.M.,et al, 1982
Pergolide in Late-Stage Parkinson Disease
Ann Neurol 12:243-247, Lang,A.E.,et al, 1982
Further Studies with Pergolide in Parkinson Disease
Neurol 32:1181-1184, Lieberman,A.N.,et al, 1982
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981